* TG Therapeutics Inc reported a quarterly adjusted loss of 7 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of seven analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -12 cents to 5 cents per share.
* Revenue rose 713.5% to $63.47 million from a year ago; analysts expected $54.61 million.
* TG Therapeutics Inc's reported EPS for the quarter was a loss of 7 cents.
* The company reported a quarterly loss of $10.71 million.
* TG Therapeutics Inc shares had fallen by 10.2% this quarter and lost 20.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 66% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for TG Therapeutics Inc is $39.00 This summary was machine generated from LSEG data May 1 at 06:51 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.04 -0.07 Missed
Dec. 31 2023 -0.10 -0.10 Met
Sep. 30 2023 0.12 0.73 Beat
Jun. 30 2023 -0.25 -0.34 Missed
Comments